Meg Parker, PhD, is a skilled professional in computational genetics with extensive experience in biopharmaceutical research and development. Currently serving as Director of Computational Genetics at Beam Therapeutics since December 2021, Meg previously held the position of Associate Director in the same field. Prior experience includes roles as Senior Scientist and Scientist at Alnylam Pharmaceuticals from September 2018 to November 2021, and a post-doctoral research fellowship at Harvard Medical School & Brigham and Women's Hospital from July 2015 to August 2018. Meg Parker obtained a Doctor of Philosophy (Ph.D.) in Epidemiology from Johns Hopkins Bloomberg School of Public Health, where a Master’s Degree in Genetic Epidemiology was also earned. Education culminated in a Bachelor’s Degree in Cell Biology and Community Health from Tufts University.
This person is not in any teams
This person is not in any offices